Expanding indications for biotechnology agents.
Many biotechnology products currently on the market were initially approved for indications affecting only a small number of patients. However, pharmaceutical manufacturers have continued to study these agents for potential new therapeutic uses. The result is that several of these products are now approved for multiple uses involving large patient populations. In many cases, the biotechnology agents are being used in patients for whom no effective therapy was previously available.
Piascik
P
P
University of Kentucky College of Pharmacy, Lexington, USA.
D001709:Biotechnology / Q000639:trends*; D017277:Drug Approval; D016298:Hematopoietic Cell Growth Factors / Q000627:therapeutic use; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D016853:Muromonab-CD3 / Q000627:therapeutic use; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use
D016298:Hematopoietic Cell Growth Factors; D016898:Interferon-alpha; D016853:Muromonab-CD3; D010959:Tissue Plasminogen Activator